litlas
Log inCreate account

Philip J. Johnson

Active 1978–2025

Also published as
Philip J Johnson
169
Papers
35,390
Citations
106
h-index
166
i10-index

Citations

Citations per year for Philip J. Johnson1979: 1 citations1980: 1 citations1981: 1 citations1982: 3 citations1983: 3 citations1984: 6 citations1985: 10 citations1986: 5 citations1987: 9 citations1988: 11 citations1989: 8 citations1990: 6 citations1991: 13 citations1992: 20 citations1993: 20 citations1994: 37 citations1995: 33 citations1996: 28 citations1997: 32 citations1998: 67 citations1999: 78 citations2000: 93 citations2001: 143 citations2002: 197 citations2003: 151 citations2004: 240 citations2005: 207 citations2006: 213 citations2007: 197 citations2008: 284 citations2009: 179 citations2010: 243 citations2011: 203 citations2012: 251 citations2013: 182 citations2014: 191 citations2015: 229 citations2016: 205 citations2017: 212 citations2018: 253 citations2019: 948 citations2020: 1,051 citations2021: 1,085 citations2022: 828 citations2023: 674 citations2024: 1,037 citations2025: 373 citations2026: 7 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,395 citing papers, 19.7% of this breakdownChina: 2,234 citing papers, 18.3% of this breakdownJapan: 785 citing papers, 6.5% of this breakdownUnited Kingdom: 708 citing papers, 5.8% of this breakdownItaly: 638 citing papers, 5.2% of this breakdownGermany: 543 citing papers, 4.5% of this breakdownHong Kong: 450 citing papers, 3.7% of this breakdownFrance: 417 citing papers, 3.4% of this breakdownCanada: 361 citing papers, 3% of this breakdownSpain: 346 citing papers, 2.8% of this breakdownTaiwan: 318 citing papers, 2.6% of this breakdownSouth Korea: 307 citing papers, 2.5% of this breakdown
0%19.7%Other 22%

Institutions

Fields

  • Medicine73.9%
  • Biochemistry, Genetics and Molecular Biology15.8%
  • Neuroscience3.3%
  • Immunology and Microbiology1.4%
  • Engineering1%
  • Veterinary0.9%
  • Other3.7%

Topics

  • Hepatocellular Carcinoma Treatment and Prognosis12.9%
  • Liver Disease Diagnosis and Treatment7%
  • Cholangiocarcinoma and Gallbladder Cancer Studies4.3%
  • Hepatitis B Virus Studies2.8%
  • Liver Disease and Transplantation2.3%
  • Hepatitis C virus research2.2%
  • Other68.5%

Coauthors

All papers

Open in search
  1. Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

    Authors: Philip J. Johnson, Sarah Berhane, Chiaki Kagebayashi, Shinji Satomura, Mabel Teng, Helen L. Reeves, James O’Beirne, Richard Fox, Anna Skowrońska, Daniel H. Palmer, Winnie Yeo, Frankie Mo, Paul B.S. Lai, Mercedes Iñarrairaegui, Stephen L. Chan, Bruno Sangro, Rebecca A. Miksad, Toshifumi Tada, Takashi Kumada, Hidenori Toyoda - Journal of Clinical Oncology 2014 cited by 2,755

  2. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

    Authors: Joong‐Won Park, Minshan Chen, M. Colombo, Lewis R. Roberts, Myron Schwartz, Pei‐Jer Chen, Masatoshi Kudo, Philip J. Johnson, Samuel Wagner, Lucinda Orsini, Morris Sherman - Liver International 2015 cited by 1,256

  3. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

    Authors: Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, Takuji Torimura, Nobukazu Tanabe, Hiroshi Aikata, Namiki Izumi, Takahiro Yamasaki, Shunsuke Nojiri, Keisuke Hino, Hidetaka Tsumura, Teiji Kuzuya, Norio Isoda, Kohichiroh Yasui, Hajime Aino, Akio Ido, Naoto Kawabe, Kazuhiko Nakao, Yoshiyuki Wada, Osamu Yokosuka, Kenichi Yoshimura, Takuji Okusaka, Junji Furuse, Norihiro Kokudo, Kiwamu Okita, Philip J. Johnson, Yasuaki Arai - Gut 2019 cited by 723

  4. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma

    Authors: Philip J. Johnson, Qing Zhou, Doan Y Dao, Yuk Ming Dennis Lo - Nature Reviews Gastroenterology & Hepatology 2022 cited by 318

  5. openalex_id:w4200584065

    Authors: Tom H. Karlsen, Nick Sheron, Shira Zelber‐Sagi, Patrizia Carrieri, Geoffrey Dusheiko, Elisabetta Bugianesi, Rachel Pryke, Sharon Hutchinson, Bruno Sangro, Natasha K. Martin, Michele Cecchini, Mae Dirac, Annalisa Belloni, Miquel Serra‐Burriel, Cyriel Y. Ponsioen, Brittney S Sheena, Aliénor Lerouge, Marion Devaux, Nick Scott, Margaret Hellard, Henkjan J. Verkade, Ekkehard Sturm, Giulio Marchesini, Hannele Yki‐Järvinen, Christopher D. Byrne, Giovanni Targher, Aviad Tur‐Sinai, Damon Barrett, Michael Ninburg, Tatjana Reić, Alison Taylor, Tim Rhodes, Carla Treloar, Claus Petersen, Christoph Schramm, Robert Flisiak, Marieta Simonova, Albert Parés, Philip J. Johnson, Alessandro Cucchetti, Isabel Graupera, Christos Lionis, Elisa Pose, Núria Fabrellas, Ann T., Juan Manuel Mendive, Vincenzo Mazzaferro, Harry Rutter, Helena Cortez‐Pinto, Déirdre Kelly, Robyn Burton, Jeffrey V. Lazarus, Pere Ginès, Marı́a Buti, Philip N. Newsome, Patrizia Burra, Michael P. Manns cited by 245

  6. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

    Authors: Rong Fan, George Papatheodoridis, Jian Sun, Hamish Innes, Hidenori Toyoda, Qing Xie, Shuyuan Mo, Vana Sypsa, Indra Neil Guha, Takashi Kumada, Junqi Niu, George Ν. Dalekos, Satoshi Yasuda, Eleanor Barnes, Jianqi Lian, Vithika Suri, Ramazan Idılman, Stephen T. Barclay, Xiaoguang Dou, Thomas Berg, Peter Hayes, John F. Flaherty, Yuanping Zhou, Zhengang Zhang, Marı́a Buti, Sharon Hutchinson, Yabing Guo, José Luís Calleja, Lanjia Lin, Longfeng Zhao, Yongpeng Chen, Harry L.A. Janssen, Chaonan Zhu, Lei Shi, Xiaoping Tang, Anuj Gaggar, Lai Wei, Jidong Jia, William L. Irving, Philip J. Johnson, Pietro Lampertico, Jinlin Hou - Journal of Hepatology 2020 cited by 349

  7. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection

    Authors: Anthony W.H. Chan, Jian‐Hong Zhong, Sarah Berhane, Hidenori Toyoda, Alessandro Cucchetti, Keqing Shi, Toshifumi Tada, Charing C. N. Chong, Bang‐De Xiang, Le‐Qun Li, Paul B.S. Lai, Vincenzo Mazzaferro, Marta García‐Fiñana, Masatoshi Kudo, Takashi Kumada, Sasan Roayaie, Philip J. Johnson - Journal of Hepatology 2018 cited by 551

  8. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis

    Authors: Jan Best, Lars P. Bechmann, Jan‐Peter Sowa, Svenja Sydor, Alexander Dechêne, Kristina Pflanz, Sotiria Bedreli, Clemens Schotten, Andreas Geier, Thomas Berg, Janett Fischer, Arndt Vogel, Heike Bantel, Arndt Weinmann, Jörn M. Schattenberg, Yvonne Huber, Henning Wege, Johann von Felden, Kornelius Schulze, Dominik Bettinger, Robert Thimme, Friedrich Sinner, Kerstin Schütte, Karl Heinz Weiss, Hidenori Toyoda, Satoshi Yasuda, Takashi Kumada, Sarah Berhane, Marc Wichert, Dominik Heider, Guido Gerken, Philip J. Johnson, Ali Canbay - Clinical Gastroenterology and Hepatology 2019 cited by 289

  9. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial

    Authors: Tim Meyer, Richard Fox, Yuk Ting, Paul J. Ross, Martin W. James, Richard Sturgess, Clive Stubbs, Deborah Stocken, Lucy Wall, Anthony Watkinson, Nigel Hacking, T.R. Jeffry Evans, Peter L. Collins, Richard Hubner, David Cunningham, John Primrose, Philip J. Johnson, Daniel H. Palmer - ˜The œLancet. Gastroenterology & hepatology 2017 cited by 497

  10. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients

    Authors: Sarah Berhane, Hidenori Toyoda, Toshifumi Tada, Takashi Kumada, Chiaki Kagebayashi, Shinji Satomura, Nóra Schweitzer, Arndt Vogel, Michael P. Manns, Julia Benckert, Thomas Berg, Maria Ebker, Jan Best, Alexander Dechêne, Guido Gerken, JF Schlaak, Arndt Weinmann, Marcus A. Wörns, Peter R. Galle, Winnie Yeo, Frankie Mo, Stephen L. Chan, Helen L. Reeves, Trevor F. Cox, Philip J. Johnson - Clinical Gastroenterology and Hepatology 2016 cited by 323

  11. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma

    Authors: Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, Takuji Torimura, Nobukazu Tanabe, Hiroshi Aikata, Namiki Izumi, Takahiro Yamasaki, Shunsuke Nojiri, Keisuke Hino, Hidetaka Tsumura, Teiji Kuzuya, Norio Isoda, Michihisa Moriguchi, Hajime Aino, Akio Ido, Naoto Kawabe, Kazuhiko Nakao, Yoshiyuki Wada, Sadahisa Ogasawara, Kenichi Yoshimura, Takuji Okusaka, Junji Furuse, Norihiro Kokudo, Kiwamu Okita, Philip J. Johnson, Yasuaki Arai, on behalf of the TACTICS Study Group - Liver Cancer 2022 cited by 128

  12. The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers

    Authors: Philip J. Johnson, Sarah Pirrie, Trevor F. Cox, Sarah Berhane, Mabel Teng, Daniel H. Palmer, Janet Morse, Diana Hull, Gillian Patman, Chiaki Kagebayashi, Syed A. Hussain, Janine Graham, Helen L. Reeves, Shinji Satomura - Cancer Epidemiology Biomarkers & Prevention 2013 cited by 335

  13. The ALBI score: From liver function in patients with HCC to a general measure of liver function

    Authors: Hidenori Toyoda, Philip J. Johnson - JHEP Reports 2022 cited by 194

  14. The role of hepatic resection in the treatment of hepatocellular cancer

    Authors: Sasan Roayaie, Ghalib Jibara, Parissa Tabrizian, Joong‐Won Park, Jijin Yang, Lünan Yan, Myron Schwartz, Guohong Han, Francesco Izzo, Mishan Chen, Jean‐Frédéric Blanc, Philip J. Johnson, Masatoshi Kudo, Lewis R. Roberts, Morris Sherman - Hepatology 2015 cited by 415

  15. Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma

    Authors: Antonio Daniele Pinna, Tian Yang, Vincenzo Mazzaferro, Luciano De Carlis, Jian Zhou, Sasan Roayaie, Feng Shen, Carlo Sposito, Matteo Cescon, Stefano Di Sandro, Yifeng He, Philip J. Johnson, Alessandro Cucchetti - Annals of Surgery 2018 cited by 219

  16. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial

    Authors: Masatoshi Kudo, Kazuomi Ueshima, Osamu Yokosuka, Sadahisa Ogasawara, Shuntaro Obi, Namiki Izumi, Hiroshi Aikata, Hiroaki Nagano, Etsuro Hatano, Yutaka Sasaki, Keisuke Hino, Takashi Kumada, Kazuhide Yamamoto, Yasuharu Imai, Shouta Iwadou, Chikara Ogawa, Takuji Okusaka, Fumihiko Kanai, Kohei Akazawa, Kenichi Yoshimura, Philip J. Johnson, Yasuaki Arai, Masatoshi Kudo, Kazuomi Ueshima, Osamu Yokosuka, Sadahisa Ogasawara, Shuntaro Obi, Namiki Izumi, Hiroshi Aikata, Hiroaki Nagano, Etsuro Hatano, Yutaka Sasaki, Keisuke Hino, Takashi Kumada, Kazuhide Yamamoto, Yasuharu Imai, Shouta Iwadou, Chikara Ogawa, Takuji Okusaka, Fumihiko Kanai, Kohei Akazawa, Kenichi Yoshimura, Philip Johnson, Yasuaki Arai - ˜The œLancet. Gastroenterology & hepatology 2018 cited by 309

  17. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer

    Authors: Latha Kadalayil, Roberto Benini, Lalit Pallan, James O’Beirne, Laura Marelli, Dominic Yu, Allan Hackshaw, Richard Fox, Philip J. Johnson, Andrew K. Burroughs, Daniel H. Palmer, Tim Meyer - Annals of Oncology 2013 cited by 378

  18. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response‐Based Approach

    Authors: Guohong Han, Sarah Berhane, Hidenori Toyoda, Dominik Bettinger, Omar Elshaarawy, Anthony W.H. Chan, Martha M. Kirstein, Cristina Mosconi, Florian Hucke, Daniel H. Palmer, David J. Pinato, Rohini Sharma, Diego Ottaviani, Jeong Won Jang, Tim A. Labeur, Otto M. van Delden, Mario Pirisi, Nick Stern, Bruno Sangro, Tim Meyer, Waleed Fateen, Marta García‐Fiñana, Asmaa Gomaa, Imam Waked, Eman Rewisha, Guruprasad P. Aithal, Simon Travis, Masatoshi Kudo, Alessandro Cucchetti, Markus Peck‐Radosavljevic, R. Bart Takkenberg, Stephen L. Chan, Arndt Vogel, Philip J. Johnson - Hepatology 2019 cited by 130

  19. Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

    Authors: Philip J. Johnson, Shukui Qin, Joong‐Won Park, Ronnie T.P. Poon, Jean‐Luc Raoul, Philip A. Philip, Chih‐Hung Hsu, Tsung‐Hui Hu, Jeong Heo, Jianming Xu, Ligong Lu, Yee Chao, Éveline Boucher, Kwang‐Hyub Han, Seung Woon Paik, Jorge Alberto Robles-Aviña, Masatoshi Kudo, Lünan Yan, Abhasnee Sobhonslidsuk, Д. В. Комов, Thomas Decaens, Won Young Tak, Long‐Bin Jeng, David Liu, Rana Ezzeddine, Ian Walters, Ann‐Lii Cheng - Journal of Clinical Oncology 2013 cited by 775

  20. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis

    Authors: Julien Edeline, Ángela Lamarca, Mairéad G. McNamara, Timothy W. Jacobs, Richard Hubner, Dan Palmer, Bas Groot Koerkamp, Philip J. Johnson, Boris Guiu, Juan W. Valle - Cancer Treatment Reviews 2021 cited by 108

  21. Quantitative Analysis of Fetal DNA in Maternal Plasma and Serum: Implications for Noninvasive Prenatal Diagnosis

    Authors: Yuk Ming Dennis Lo, Mark Tein, Tze Kin Lau, Christopher J. Haines, Tse Ngong Leung, Priscilla M.K. Poon, James S. Wainscoat, Philip J. Johnson, Allan M.Z. Chang, N M Hjelm - The American Journal of Human Genetics 1998 cited by 1,658

  22. Limited regeneration in long acellular nerve allografts is associated with increased Schwann cell senescence

    Authors: Maryam Saheb-Al-Zamani, Yan Yan, Scott J. Farber, Daniel A. Hunter, Piyaraj Newton, Matthew D. Wood, Sheila A. Stewart, Philip J. Johnson, Susan E. Mackinnon - Experimental Neurology 2013 cited by 215

  23. Regenerative Peripheral Nerve Interface Viability and Signal Transduction with an Implanted Electrode

    Authors: Theodore A. Kung, Nicholas B. Langhals, David C. Martin, Philip J. Johnson, Paul S. Cederna, Melanie G. Urbanchek - Plastic & Reconstructive Surgery 2014 cited by 177

  24. A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma

    Authors: Winnie Yeo, Tony Mok, Benny Zee, Thomas W. T. Leung, Paul B.S. Lai, Wan Yee Lau, Jane Koh, Frankie Mo, Simon C.H. Yu, Anthony T.�C. Chan, Pun Hui, Brigette Ma, Kwok Chi Lam, Wing Ming Ho, Herman Wong, Amanda M. Y. Tang, Philip J. Johnson - JNCI Journal of the National Cancer Institute 2005 cited by 589